# APIMEDS PHARMACEUTICALS US I (APUS)

> Institutional ownership reported to the SEC as of Q2 2026, from Form 13F filings. Source: https://holderbook.com/stocks/APUS/

- Reporting holders: 7
- Reported value: $383.7K
- Shares held by institutions: 426,282 of 15,091,177 outstanding
- Held through calls: 0.0%
- Held through puts: 0.0%

A 13F reports long US equity positions only. Shorts, bonds, foreign listings and cash are not visible here, and positions are disclosed up to 45 days after the quarter ends.

## Largest holders

| Manager | Value | Shares | Share of their book | Quarters held |
|---|---|---|---|---|
| [Hemenway Trust Co LLC](https://holderbook.com/funds/1494234-hemenway-trust-co-llc/) | $246.6K | 274,000 | 0.0% | 4 |
| [VANGUARD CAPITAL MANAGEMENT LLC](https://holderbook.com/funds/2100119-vanguard-capital-management-llc/) | $57.3K | 63,654 | 0.0% | 2 |
| [GEODE CAPITAL MANAGEMENT, LLC](https://holderbook.com/funds/1214717-geode-capital-management-llc/) | $31.6K | 35,114 | 0.0% | 4 |
| [VANGUARD FIDUCIARY TRUST CO](https://holderbook.com/funds/933478-vanguard-fiduciary-trust-co/) | $21.6K | 24,039 | 0.0% | 2 |
| [JANE STREET GROUP, LLC](https://holderbook.com/funds/1595888-jane-street-group-llc/) | $14.4K | 15,993 | 0.0% | 1 |
| [UBS Group AG](https://holderbook.com/funds/1610520-ubs-group-ag/) | $10.6K | 11,818 | 0.0% | 3 |
| [Tower Research Capital LLC (TRC)](https://holderbook.com/funds/1533421-tower-research-capital-llc-trc/) | $1.5K | 1,664 | 0.0% | 1 |

## Quarter by quarter

| Quarter | Holders | Reported value |
|---|---|---|
| Q2 2026 | 7 | $383.7K |
| Q1 2026 | 6 | $803.0K |
| Q4 2025 | 7 | $648.9K |
| Q3 2025 | 8 | $711.8K |
| Q2 2025 | 6 | $490.2K |